# Murat Tunaboylu

> Murat Tunaboylu is the co-founder and CEO of Antiverse, a Cardiff- and Boston-based AI-native biologics company designing de novo antibodies for historically undruggable targets like GPCRs and ion channels. A software engineer who spent years automating gene synthesis at Thermo Fisher and building lab robots for cancer research before starting a company that uses generative models to design antibodies, he raised a $9.3M Series A in March 2026 and struck a research deal with the Cystic Fibrosis Foundation the same week.

- **Role:** Co-founder and CEO at Antiverse
- **Organizations:** Antiverse, Svarlight, Deep Science Ventures, Thermo Fisher Scientific
- **Nationality:** Turkish
- **Education:** BSc, Electrical Engineering, Yildiz Technical University, MSc, Computer Engineering, Bahçeşehir Üniversitesi
- **Known for:** Co-founded Antiverse and grew it to 38 employees across Cardiff and Boston, Raised over $20M in total funding for Antiverse, Closed $9.3M Series A in March 2026 led by Soulmates Ventures with participation from Innovation Investment Capital, DOMiNO Ventures, DBW, Kadmos Capital and i&i Biotech Fund

## Career timeline

- **early career** — Software engineer building high-frequency trading systems
- **mid career** — Built cell imaging software and lab robotics for cancer research
- **pre-2018** — Senior Developer for Synthetic Biology MES at Thermo Fisher Scientific, automating gene synthesis workflows
- **2018** — Co-founded Antiverse with Ben Holland in Cardiff, Wales
- **2020** — Antiverse raises £1.8M seed round
- **2023** — Antiverse raises additional $3M
- **2026-03** — Antiverse closes $9.3M Series A led by Soulmates Ventures; announces research agreement with the Cystic Fibrosis Foundation on CFTR-targeting antibodies

## Achievements

- Co-founded Antiverse and grew it to 38 employees across Cardiff and Boston
- Raised over $20M in total funding for Antiverse
- Closed $9.3M Series A in March 2026 led by Soulmates Ventures with participation from Innovation Investment Capital, DOMiNO Ventures, DBW, Kadmos Capital and i&i Biotech Fund
- Signed a research agreement with the Cystic Fibrosis Foundation to design antibodies against the extracellular region of CFTR
- Built platform Antiverse says can move from target identification to an optimized antibody in about 4 months
- Automated Thermo Fisher Scientific's gene synthesis workflows earlier in career

## Latest updates

- **2026-03** — Antiverse closes $9.3M Series A led by Soulmates Ventures and announces CF Foundation research agreement on CFTR antibodies.

## Links

- Website: https://antiverse.io
- LinkedIn: https://www.linkedin.com/in/murattunaboylu/
- Twitter/X: https://twitter.com/AntiverseHQ
- YouTube: https://www.youtube.com/@AntiverseHQ

---

Profile page: https://yespress.io/murat-tunaboylu
Published by YesPress — https://yespress.io
Last updated: 2026-07-09